Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Rhythm Pharmaceuticals (RYTM) PT Raised to $102 at Leerink Partners
July 9, 2025 4:18 PM EDTLeerink Partners analyst Faisal Khurshid raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $102.00 (from $88.00) while maintaining a Outperform rating.
The analyst comments "We are updating our estimates for RYTM following this morning's disclosure of bivamelagon Ph 2 data in acquired... More
